NGFR — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL9317148	0.62	2/20
SCHEMBL11713151	0.51	2/20
SCHEMBL11638566	0.50	2/20
SCHEMBL11638544	0.47	2/20
SCHEMBL11643204	0.47	2/20
SCHEMBL11723446	0.47	2/20
SCHEMBL11641819	0.47	2/20
SCHEMBL11640479	0.46	2/20
SCHEMBL1847171	0.44	2/20
SCHEMBL11714206	0.44	2/20
SCHEMBL4990158	0.43	2/20
SCHEMBL11641823	0.43	2/20
SCHEMBL1165265	0.43	2/20
SCHEMBL11811478	0.41	2/20
SCHEMBL2903161	0.41	2/20
SCHEMBL11641176	0.40	2/20
SCHEMBL11719383	0.40	2/20
SCHEMBL11641173	0.39	2/20
SCHEMBL11641180	0.39	2/20
SCHEMBL11065167	0.38	2/20

Clinical trials — most relevant to NGFR by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Etanercept and Methotrexate in Patients to Induce Remission in Early Arthritis (EMPIRE)	PHASE4	COMPLETED
Clinical Study Evaluating the Anticancer Effect of Pentoxiphylline in Patients With Metastatic Colorectal Cancer	PHASE4	UNKNOWN
Simvastatin Reduces Circulating Osteoprotegerin Levels in Patients With Type 2 Diabetes	PHASE4	COMPLETED
Characteristics and Mechanism of Denosumab-treated Giant Cell Tumor of Bone	PHASE3	UNKNOWN
Safety and Efficacy of the PAINLESS Nerve Growth Factor CHF6467 in Optic Pathway Glioma (OPG)	PHASE2	ACTIVE_NOT_RECRUITING
NAPO - Novel Approach for Oligospermia	PHASE1/PHASE2	COMPLETED
tDCS Associated With Peripheral Electrical Stimulation for Pain Control in Individuals With Sickle Cell Disease	PHASE2	UNKNOWN
Blocking Tumor Necrosis Factor in Ankylosing Spondylitis	PHASE2	COMPLETED
Denosumab and Nivolumab Combination As 2d-line Therapy in Stage IV NSC Lung Cancer with Bone Metastases (DENIVOS)	PHASE2	COMPLETED
TNFSF11 Inhibition and Fertility: a Prospective Study	PHASE2	COMPLETED
FITMI - First In Treating Male Infertility	PHASE2	ACTIVE_NOT_RECRUITING
Etanercept in Hidradenitis Suppurativa	PHASE2	COMPLETED
NT-NOA - Novel Treatment of Some Men With Non-Obstructive Azoospermia	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Phase II Study of Vandetanib in Individuals With Kidney Cancer	PHASE2	COMPLETED
Etanercept (Enbrel) to Treat Pain and Swelling After Third Molar Extraction	PHASE2	COMPLETED
Phase 1 Dose Escalation Study of Intra-Articular Administration of tgAAC94	PHASE1	COMPLETED
Safety and Efficacy Study of Etanercept (Enbrel) on the Response Rate of HIV-infected Subjects	PHASE1	COMPLETED
Presurgical Trial of Denosumab in Breast Cancer	EARLY_PHASE1	COMPLETED
A Retro-/Prospective, Non-interventional, Cohort Study in Adult Patients With Locally Advanced or Metastatic Tumors With a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion, Treated With Larotrectinib	nan	COMPLETED
Changes in Skin Innervation of Neurologically Asymptomatic Type 2 Diabetic Patients: the Correlation With the Diabetic Parameters and Neurotrophins.	nan	UNKNOWN
Novel Biomarkers in Inflammatory Bowel Disease	nan	COMPLETED
Effect of Smoking on Periodontal Therapy in Periodontitis	nan	COMPLETED
Er,Cr:YSGG Laser Application in Peri-implantitis	nan	COMPLETED
NGF, TrKA,p75NTR in Men With ED and Diabetes With or Without MS	nan	UNKNOWN
Yogic Breathing Changes Salivary Components	nan	COMPLETED
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors	nan	ACTIVE_NOT_RECRUITING
Using of Costimulatory and co Inhibatory Immune Checkpoints as Diagnostic and Prognostic in Breast Cancer	nan	UNKNOWN
Interleukin-34 Level in Periodontal Disease	nan	UNKNOWN
Biomarkers in Blood and Tissue Samples From Patients With Newly Diagnosed Neuroblastoma	nan	COMPLETED
Immune Checkpoints in Predicting Response to Neoadjuvant Therapy in Rectal Cancer	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a NGFR binder may also engage these)

Protein	Name	Similarity
Q9Z0W1	—	0.997	Q9Z0W1 →
P07174	—	0.995	P07174 →
P18519	—	0.985	P18519 →
P50555	—	0.977	P50555 →
O19131	—	0.975	O19131 →
TNFRSF1A	Tumor necrosis factor receptor superfamily member 1A	0.969	landscape →
Q4R4I0	—	0.963	Q4R4I0 →
TERF2IP	Telomeric repeat-binding factor 2-interacting protein 1	0.963	landscape →
Q05716	—	0.960	Q05716 →
P21744	—	0.958	P21744 →
Q92956	—	0.958	Q92956 →
Q93038	—	0.958	Q93038 →
P47879	—	0.957	P47879 →
P49797	—	0.957	P49797 →
Q0VCT3	—	0.957	Q0VCT3 →
PML	Protein PML	0.956	landscape →
P24854	—	0.956	P24854 →
P20959	—	0.956	P20959 →
Q496Y0	—	0.955	Q496Y0 →
Q96MU8	—	0.955	Q96MU8 →
IGFBP4	Insulin-like growth factor-binding protein 4	0.955	landscape →
P43489	—	0.955	P43489 →
E1BBQ2	—	0.955	E1BBQ2 →
Q8R007	—	0.954	Q8R007 →
Q6UWJ8	—	0.954	Q6UWJ8 →
Q3ZTK5	—	0.954	Q3ZTK5 →
Q66T02	—	0.953	Q66T02 →
P97260	—	0.953	P97260 →
Q8K5A9	—	0.953	Q8K5A9 →
D4A6L0	—	0.952	D4A6L0 →